Top

Published in:

01-12-2012 | Dementias - Short communication

Nigral Tau pathology and striatal amyloid-β deposition does not correlate with striatal dopamine deficit in Alzheimer’s disease

Authors: Tabea H. Schauer, Maximilian Lochner, Gabor G. Kovacs

Published in: Journal of Neural Transmission | Issue 12/2012

Abstract

Extrapyramidal symptoms may appear in Alzheimer’s disease (AD). In the present study, using morphometric immunohistochemistry in 34 cases with AD-related pathology, we evaluated whether nigral burden of tau pathology or striatal burden of amyloid-β deposition correlates with dopamine transporter (DAT) expression in the striatum. Our observations show a lack of correlation between these variables and support the notion that lower striatal DAT expression in AD patients suggests concomitant nigral α-synuclein pathology. Extrapyramidal symptoms may have a complex background in AD.

Attems J, Quass M, Jellinger KA (2007) Tau and α-synuclein brainstem pathology in Alzheimer disease: relation with extrapyramidal signs. Acta Neuropathol 113(1):53–62PubMedCrossRef

Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82(4):239–259PubMedCrossRef

Ceravolo R, Volterrani D, Gambaccini G, Bernardini S, Rossi C, Logi C, Tognoni G, Manca G, Mariani G, Bonuccelli U, Murri L (2004) Presynaptic nigro-striatal function in a group of Alzheimer’s disease patients with parkinsonism: evidence from a dopamine transporter imaging study. J Neural Transm 111(8):1065–1073PubMedCrossRef

Ciliax BJ, Drash GW, Staley JK, Haber S, Mobley CJ, Miller GW, Mufson EJ, Mash DC, Levey AI (1999) Immunocytochemical localization of the dopamine transporter in human brain. J Comp Neurol 409(1):38–56PubMedCrossRef

Costa DC, Walker Z, Walker RW, Fontes FR (2003) Dementia with Lewy bodies versus Alzheimer’s disease: role of dopamine transporter imaging. Mov Disord 18(Suppl 7):S34–S38PubMedCrossRef

Giros B, Carron MG (1993) Molecular characterization of the dopamine transporter. Trends Pharmacol Sci 14(2):43–49PubMedCrossRef

Kovacs GG, Milenkovic IJ, Preusser M, Budka H (2008) Nigral burden of α-synuclein correlates with striatal dopamine deficit. Mov Disord 23(11):1608–1612PubMedCrossRef

Kovacs GG, Botond G, Budka H (2010) Protein coding of neurodegenerative dementias: the neuropathological basis of biomarker diagnostics. Acta Neuropathol 119(4):389–408PubMedCrossRef

Kovacs GG, Molnar K, Laszlo L, Ströbel T, Botond G, Hönigschnabl S, Reiner-Concin A, Palkovits M, Fischer P, Budka H (2011) A peculiar constellation of tau pathology defines a subset of dementia in the elderly. Acta Neuropathol 122:205–222PubMedCrossRef

Marshall V, Grosset DG (2003a) Role of dopamine transporter imaging in the diagnosis of atypical tremor disorders. Mov Disord 18(Suppl 7):S22–S27PubMedCrossRef

Marshall V, Grosset D (2003b) Role of dopamine transporter imaging in routine clinical practice. Mov Disord 18(12):1415–1423PubMedCrossRef

McKeith IG (2002) Dementia with Lewy bodies. Br J Psychiatry 180:144–147PubMedCrossRef

McKeith I, Fairbairn A, Perry R, Thompson P (1992) Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ 305(6855):673–678PubMedCrossRef

McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, Cicin-Sain A, Ferrara R, Spiegel R (2000) Efficacy of rivastigmine in dementia with Lewy bodies: a randomized, double blind, placebo-controlled international study. Lancet 356(9247):2031–2036PubMedCrossRef

McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VM, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology 65(12):1863–1872PubMedCrossRef

Piccini PP (2003) Dopamine transporter: basic aspects and neuroimaging. Mov Disord 18(Suppl 7):S3–S8PubMedCrossRef

Poewe W, Scherfler C (2003) Role of dopamine transporter imaging in investigation of parkinsonian syndromes in routine clinical practice. Mov Disord 18(Suppl 7):S16–S21PubMedCrossRef

Thal DR, Rüb U, Orantes M, Braak H (2002) Phases of Aβ-deposition in the human brain and its relevance for the development of AD. Neurology 58(12):1791–1800PubMedCrossRef

Title: Nigral Tau pathology and striatal amyloid-β deposition does not correlate with striatal dopamine deficit in Alzheimer’s disease
Authors: Tabea H. Schauer
Maximilian Lochner
Gabor G. Kovacs
Publication date: 01-12-2012
Publisher: Springer Vienna
Published in: Journal of Neural Transmission / Issue 12/2012
Print ISSN: 0300-9564
Electronic ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-012-0832-9

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Nigral Tau pathology and striatal amyloid-β deposition does not correlate with striatal dopamine deficit in Alzheimer’s disease

Abstract

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2012

Does structural neuroimaging reveal a disturbance of iron metabolism in Parkinson’s disease? Implications from MRI and TCS studies

The history of the research of iron in parkinsonian substantia nigra

Proteasome inhibition leads to early loss of synaptic proteins in neuronal culture

Different molecular pathologies result in similar spatial patterns of cellular inclusions in neurodegenerative disease: a comparative study of eight disorders

Early serotonin and kynurenine research: Slava Lapin (1930–2012)

Association of functional COMT Val108/Met polymorphism with smoking cessation in a nicotine replacement therapy